Funded Sarcoma Research Projects
Research That
Makes a Difference
Rein in Sarcoma funds research which directly contributes to a broader understanding of sarcoma, supports new treatment strategies, and helps improve outcomes for patients of all ages. The projects we support are chosen for their potential to make meaningful clinical impact and to expand knowledge in areas where progress is most needed.
Each funded project represents the dedication of scientists, clinicians, and patient advocates working together to bring new possibilities to the sarcoma community.
Rein in Sarcoma’s Funded Projects
Click to learn about the research we have funded at top research institutions such as the University of Minnesota, Mayo Clinic, Children’s Hospitals, and Clinics of Minnesota.
2025 1 project · $5,000
Project Title
Principal Investigator
Institution
Amount
LMS SPORE
Dr. Baker & Team
SARC
$5,000
2024 4 projects · $186,665.56
Project Title
Principal Investigator
Institution
Amount
LMS SPORE
Dr. Baker & Team
SARC
$5,000
University of Calgary – Biology, mechanisms, and targetability of cancer-associated fibroblasts in rhabdomyosarcoma
Aru Narendran MD, PhD. FAAP
University of Calgary
$55,000
University of Minnesota – Unraveling the Mechanisms of Immune Evasion in CIC::DUX4 Sarcoma
Dr. Darko Boshnakovski
University of Minnesota
$50,000
Aveni Foundation – DeltaRex-G Manufacture in Memory of Yunhui Chae-Banks
Dr. Erlina Gordon
Aveni Foundation
$76,665.56
2023 4 projects · $95,000
Project Title
Principal Investigator
Institution
Amount
Targeting the Cell Cycle and Autophagy Reciprocal Communication Pathways in Sarcomas
Dr. Erin Dickerson
University of Minnesota
$50,000
Clarifying the Molecular Profile of DICER1-related sarcomas
Dr. Kris Ann Schultz
Children’s Minnesota
$15,000
Sarcoma Resection Guided by Intraoperative Indocyanine Green Dye Fluorescence Angiography
Matthew T. Houdek, MD & Mikaela H. Sullivan, MD
Mayo Clinic
$25,000
LMS SPORE
Dr. Baker & Team
SARC
$5,000
2022 2 projects · $104,000
Project Title
Principal Investigator
Institution
Amount
Identification of new strategies to therapeutically intervene for rhabdomyosarcomas
Berkley E. Gryder, PhD
Case Western Reserve University
$54,000
Characterization of Ewing Sarcoma patient-derived induced pluripotent stem cells
Beau Webber, PhD
University of Minnesota
$50,000
2021 3 projects · $90,000
Project Title
Principal Investigator
Institution
Amount
Identifying and Characterizing the Cells that Create the Primary and Metastatic Sarcoma Niche
Jaime Modiano
UMN
$50,000
DICER1-related sarcomas
Kris Ann Schultz Damon Olson
Childrens
$20,000
Clinical and laboratory tools to evaluate treatment tolerability in older patients with soft tissue sarcoma
Thanh Ho
Mayo Clinic
$20,000
2020 5 projects · $190,000
Project Title
Principal Investigator
Institution
Amount
eBAT as a Modulator of the Myeloid Immune Checkpoint in Cancer
Dr. Jaime Modiano
UMN
$50,000
Using Propranolol to Generate an Anti-Tumor Microenvironment
Dr. Erin Dickerson
UMN
$50,000
Computationally Deciphering the Paths of Genomic Catastropohe in Osteosarcoma
Dr. Ruping Sun
UMN
$50,000
DICER1-related Genitourinary Sarcomas
Dr. Kris Ann P. Schultz
Children’s Minnesota
$15,000
Targeting the Immune Checkpoint B7-H3 for the Treatment of Rhabdomyosarcoma.
Dr. Fabrice Lucien-Matteoni
Mayo Clinic
$25,000
2019 5 projects · $195,000
Project Title
Principal Investigator
Institution
Amount
MYOG: Promoter-Controlled Oncolytic Adenovirus to Treat PAX3-FOXO1-Positive Rhabdomyosarcoma
Dr. Masato Yamamoto / Hideki Yoshida
UMN
$50,000
SHH signaling genetic alterations: A relevant and targetable trait in peripheral nerve sheath sarcomas
Dr. David Largaespada
UMN
$50,000
Registry-based analysis of risk and survival for young-onset sarcomas
Dr. Logan Spector
UMN
$50,000
2019 Integrated Proteomic and Transcriptomic Profiling of Rhabdomyosarcoma Reveals Target Antigens for Immune-Based Therapies
Dr. Patricio Gargollo
Mayo
$25,000
Expanding Opportunities For Early Detection of Sarcoma
Dr. Megan Hilgers and Dr. Kris Ann P. Schultz
Children’s Minnesota
$20,000
2018 6 projects · $193,000
Project Title
Principal Investigator
Institution
Amount
Predicting relapse and response to chemotherapy in sarcoma
Dr. Amy Skubitz
UMN
$49,000
Retrospective and Prospective Comparison of Prognostic Transcriptional Biomarkers in Osteosarcoma using NanoString RNA profiling
Dr. Aaron Sarver / Dr. Edward Cheng
UMN
$49,000
Reprogramming cholesterol metabolism in sarcomas using adrenergic receptor antagonists
Dr. Erin Dickerson
UMN
$25,000
Identification of novel drivers of Ewing Sarcoma through engineered transformation of cells with differing levels of African admixture
Dr. Beau Weber
UMN
$25,000
Pilot Study of Circulating Cell Free Tumor DNA as a Biomarket in Sarcoma
Dr. Brittany Siontis / Dr. Steven Robinson
Mayo
$30,000
Identifying Gene Fusions in Pleuropulmonary Blastoma
Dr. Kris Ann Schultz
Children’s Minnesota
$15,000
2017 7 projects · $170,000
Project Title
Principal Investigator
Institution
Amount
Engaging the Immune system as a strategy for sarcoma therapy
Dr. Antonella Borgatti
UMN
$40,000
Effects of beta-adrenergic receptor antagonists on sarcoma radiosensitivity
Dr. Jessica Lawrence
UMN
$35,000
Enhancement of the Response of Sarcoma to SBRT by Targeting HIF-1a
Dr. L. Chinsoo Cho
UMN
$25,000
Defining the Immunologic Landscape of Spontaneous Canine Osteosarcoma
Dr. Jaime Modiano
UMN
$25,000
Targeting Autophagy as a Therapeutic Strategy in Osteosarcoma
Dr. Avudaiappan Maran
Mayo Clinic
$25,000
Identifying Blood-Based Biomarkers to Improve Outcome in Pleuropulmonary Blastoma
Dr. Kris Ann Schultz
Children’s Minnesota
$15,000
In Support of the SARC Specialized program in Research Excellence (SPORE) application
Laurence Baker
SARC
$ 5,000
2016 3 projects · $122,450
Project Title
Principal Investigator
Institution
Amount
The impact of Beta Adrenergic receptors
Dr. Erin Dickerson
UMN
$50,000
A better process for predicting GIST reoccurrence and other soft tissue sarcomas
Dr. Amy Skubitz
UMN
$23,000
Improving the survival rate of Osteosarcoma patients
Dr. Subbaya Subramanian
UMN
$49,450
2015 5 projects · $125,000
Project Title
Principal Investigator
Institution
Amount
The use of FDG-PET CT metabolic response to increase the therapeutic ratio of treatment for high grade, large soft tissue sarcomas
Dr. Edward Cheng
UMN
$29,000
The Role of ATRX and ALT in sarcoma
Eric Hendrickson
UMN
$24,000
Mechanism-Based Expansion of the Tumor Repertoire for an Effective Sarcoma Therapy
Dr. Jaime Modiano
UMN
$24,000
The Role of NFIB in Metastatic Pediatric Osteosarcoma
Dr. Branden Moriarity
UMN
$24,000
Enhancement of the response of sarcoma to SBRT
Dr. Kathryn Dusenbery
UMN
$24,000
2014 3 projects · $105,000
Project Title
Principal Investigator
Institution
Amount
Targeting Semaphorin-4D for Osteosarcoma Therapy
Dr. David Largaespada
UMN
$40,000
MicroRNAs in the Progression of Osteosarcoma
Dr. Subbaya Subramanian
UMN
$35,000
Correlation of Macrophage Infiltration and Microvessel Density to Clinical Outcome in Sarcoma Patients
Dr. Amy Skubitz
$30,000
2013 6 projects · $205,000
Project Title
Principal Investigator
Institution
Amount
Preclinical evaluation of Minnelide in the treatment of osteosacoma
Dr. Subbaya Subramanian
UMN
$40,000
Quantification of macrophage infiltration and microvessel density
Dr. Amy Skubitz
UMN
$40,000
Treatment of sarcoma with metformin in combination with radiotherapy
Dr. Chang Song
UMN
$20,000
Targeting Semaphorin-4D for Osteosarcoma Therapy
Dr. David Largaespada
UMN
$40,000
MicroRNAs in the Progression of Osteosarcoma
Dr. Subbaya Subramanian
UMN
$35,000
Correlation of Macrophage Infiltration and Microvessel Density to Clinical Outcome in Sarcoma Patients
Dr. Amy Skubitz
$30,000
2012 6 projects · $150,000
Project Title
Principal Investigator
Institution
Amount
Tunneling Nanotubes as Novel targets in Osteosarcoma
Dr. Emil Lou
UMN
$5,310
Treatment of sarcoma with metformin in combination with radiotherapy
Dr. Chang Song
UMN
$30,640
Functional Analysis of Low Copy Number Gain of Human 8q24 in Osteosarcoma
Anindya Bagchi
UMN
$24,460
The role of tumor cell multipotency and the microenvironment as determinants in sarcoma development and progression
Dr. Erin Dickerson
UMN
$33,230
Isolation of human osteoblasts for functional evaluation of osteosarcoma susceptibility alleles
Dr. Logan Spector
UMN
$23,130
Identification of Potential Therapeutic Targets for Sarcomas
Dr. Amy Skubitz
UMN
$33,230
2011 6 projects · $219,584
Project Title
Principal Investigator
Institution
Amount
Significance of Rb inactivation in clinical behavior of osteosarcoma
Dr. Jaime Modiano
UMN
$49,918
T-cell Targeting of Sarcomas
Dr. Xianzheng Zhou
UMN
$50,000
Allogeneic, Haploidentical NK cell Infusions for High Sarcoma Patients
Michael Verneris
UMN
$48,300
Quantification of four biomarkers that demonstrate clinical correlations in aggressive fibromatosis
Dr. Amy Skubitz
UMN
$21,366
Translational Award-Complete Genome Sequencing and Analysis of Human osteosarcoma
Dr. Subbaya Subramanian
UMN
$25,000
Translational Award-Exploring intratumoral genetic heterogeneity in rhabdomyosarcoma and osteosarcoma
Dr. David Largaespada
UMN
$25,000
2010 5 projects · $146,802
Project Title
Principal Investigator
Institution
Amount
Characterization of sarcoma stem cells and their role in chemoresistance and relapse
Dr. Amy Skubitz
UMN
$45,000
Establishment of a miRNA Serum Biomakers in Well and De-differenciated liposarcomas
Dr. Christian Ogilvie
UMN
$36,900
Fibroblast Growth Factor Receptors as Gtargets for Rhabdomyosarcoma Therapy
Dr. David Largaespada
UMN
$42,902
Patient Education video series: Amputation in pediatric sarcoma patients
Dr. Edward Cheng
UMN
$18,000
2010-2011 RIS Sarcoma Scholarship Award
Dr. Kathryn Dusenbery
UMN
$4,000
2009 6 projects · $130,000
Project Title
Principal Investigator
Institution
Amount
Clinical Correlations Associated with Genes Upregulated in Fibromatosis
Dr. Amy Skubitz
UMN
$34,500
MicroRNA Regulatory Networks in Synovial Sarcoma
Dr. Subbaya Subramanian
UMN
$34,500
Scholarship for a 2nd or 3rd year medical student with an interest in cancer and cancer education
Dr. Kathryn Dusenbery
UMN
$1,000
Therapeutic implications of P13K inhibition of E2F1 apoptotic function in osteosaracoma
Dr. Timothy Hallstrom
UMN
$24,000
Somatic mutations in Nijmegen Breakage Syndrome Gene (NBS1) in Rhabdomyosarcomas
Dr. Simona Ognjanovic
UMN
$16,000
Evaluation of PET as a Predictor of Response to Preoperative Treatment for Soft Tissue Sarcoma, a Phase II Trial
Dr. Edward Cheng
UMN
$20,000
2008 4 projects · $104,006
Project Title
Principal Investigator
Institution
Amount
Heritable Influence on VEGF Receptor Function in a Canine Endothelial STS
Dr. Jaime Modiano
UMN
$20,850
The role of p53 mutations in pediatric alveolar rhabdomyosarcoma (ARMS) and embryonal rhabdomyosarcona (ERMS)
Dr. Simona Ognjanovic
UMN
$36,936
MicroRNA Expression Profile of Synovial Sarcoma
Dr. Subbaya Subramanian
UMN
$39,020
Patient education video series: amputation, rotationplasty and limb salvage
Dr. Edward Cheng
UMN
$7,200
Current Funding
Programs
Since 2001, Rein in Sarcoma has invested more than $3 million in research and education, supporting leading institutions committed to improving sarcoma diagnosis, treatment, and patient care.
University of Minnesota
Rein in Sarcoma supports research at the University of Minnesota that aims to improve sarcoma diagnosis, treatment, and long-term outcomes for patients of all ages.

Mayo Clinic
Our funding helps Mayo Clinic investigators advance innovative approaches to sarcoma care through clinical research and scientific discovery.

University of Calgary
Through the Kasey Altman Research Fund, Rein in Sarcoma contributes to groundbreaking studies at the University of Calgary that explore new ways to understand and treat rare sarcoma subtypes.

Children’s Hospital and Clinics of Minnesota
We partner with Children’s Minnesota to support research focused on improving treatment and survivorship for children and adolescents facing sarcoma.

SARC and other international collaborations
We proudly support SARC and global research partners working together to accelerate progress and bring new hope to sarcoma patients worldwide.
University of Minnesota
Rein in Sarcoma supports research at the University of Minnesota that aims to improve sarcoma diagnosis, treatment, and long-term outcomes for patients of all ages.

Mayo Clinic
Our funding helps Mayo Clinic investigators advance innovative approaches to sarcoma care through clinical research and scientific discovery.

University of Calgary
Through the Kasey Altman Research Fund, Rein in Sarcoma contributes to groundbreaking studies at the University of Calgary that explore new ways to understand and treat rare sarcoma subtypes.

Children’s Hospital and Clinics of Minnesota
We partner with Children’s Minnesota to support research focused on improving treatment and survivorship for children and adolescents facing sarcoma.

SARC and other international collaborations
We proudly support SARC and global research partners working together to accelerate progress and bring new hope to sarcoma patients worldwide.

SARC and other international collaborations
Item description – lobortis ac odio fringilla laoreet. Morbi hendrerit in massa eget ullamcorper. Donec nec sapien orci.
Donor Recognition
Every funded project is made possible through the generosity of donors, foundations, and community partners who believe in progress and hope. We are proud to recognize their support and share the impact their contributions have on research and patient care.
Annual Reports: Transparent updates that show how funds are allocated and the outcomes they help achieve.
Donor Spotlights: Stories that celebrate the individuals and organizations whose generosity fuels discovery.
Impact Stories: Real examples of how funding supports research and improves care for patients and families.
Current and Past Projects
Our funded projects highlight the tangible outcomes of donor support and research collaboration. Each initiative reflects our commitment to transparency, innovation, and patient-centered progress.
Research Grants: Supporting cutting-edge sarcoma studies at leading institutions.
Patient Support Programs: Expanding resources and guidebooks for newly diagnosed patients and families.
Educational Initiatives: Funding training modules, symposia, and awareness campaigns to improve early diagnosis and treatment.
Apply For Funding
Rein in Sarcoma welcomes researchers and institutions dedicated to advancing knowledge and improving care for people affected by sarcoma. Our funding opportunities are designed to support innovative ideas and meaningful research that have the potential to shape the future of sarcoma treatment.
Grant Applications: Access guidelines and submission details for current and upcoming funding opportunities.
Eligibility Criteria: Learn more about who is eligible to apply and how institutions and researchers can qualify for support.
Collaboration Opportunities: Partner with Rein in Sarcoma to strengthen your research, expand its reach, and increase its impact
Partnering For Progress
By funding projects that bring together researchers, healthcare providers, and the sarcoma community, Rein in Sarcoma ensures that every investment moves us closer to meaningful breakthroughs. Together, we are building a future defined by innovation, collaboration, and hope for those affected by sarcoma.


